Anlon Healthcare, a prominent manufacturer in the pharmaceutical sector, is set to launch its initial public offering (IPO) on Tuesday, August 26, 2025. The company aims to raise approximately Rs 121 crore through a fresh issue of 1.33 crore shares. The IPO will remain open for subscription until August 29, 2025, with allotment expected to be finalized by September 1, 2025 and listing likely within three days thereafter.
For investors looking to participate, here is a detailed overview of Anlon Healthcare IPO subscription details, including the price band, lot size, GMP, and expert opinions.
The grey market premium (GMP) for Anlon Healthcare IPO currently stands at Rs 5 per share, indicating a potential listing price of around Rs 96 per share. This suggests an expected gain of approximately 5.49% per share based on current estimates from Chittorgarh.com.
The lowest GMP recorded for this IPO was Rs 0, and it has now reached its highest point of Rs 5. Investors often track GMP to gauge market sentiment and potential listing gains before the IPO opens.
Anlon Healthcare specializes in pharmaceutical chemical products, with a strong presence in pharma intermediates and APIs. The company ensures that all products comply with IP, BP, EP, JP, and USP standards, reflecting high-quality manufacturing practices.
Analyst opinions are mixed:
SMIFs Limited recommends subscribing, citing planned capacity expansion at Rajkot, Gujarat, from 400 MTPA to 1,100 MTPA. The report expects revenue to nearly double in 2-3 years, offering long-term growth potential in the Indian pharmaceutical sector.
Swastika Brokerage, however, issued an ‘avoid’ rating, noting that the company’s operations heavily rely on a single facility in Rajkot. Based on the latest financials, the stock appears fully priced, and some investors may prefer caution.
Retail investors can apply for a minimum of 1 lot (164 shares) and a maximum of 13 lots (2,132 shares), amounting to Rs 1,94,012.
Non-Institutional Investors (NIIs) can bid for 13 to 67 lots.
The IPO comprises 1.33 crore fresh shares, with the total issue size pegged at Rs 121.03 crore.
The company has set a price band of Rs 86 to Rs 91 per share, with a face value of Rs 10 per share. Allocation under the IPO is structured as follows:
Qualified Institutional Buyers (QIBs): 75% (maximum)
Retail Investors: 10% (maximum)
Non-Institutional Investors (NIIs): 15% (maximum)
The price band and allocation details are key for investors to plan their bids and understand subscription limits.
Here is a quick summary of the IPO schedule:
Subscription Open: August 26, 2025
Subscription Close: August 29, 2025
Allotment Date: September 1, 2025
Expected Listing: Within three days post-allotment
Investors should track updates from official sources to ensure timely applications.
While Anlon Healthcare’s IPO presents an opportunity in the Indian pharmaceutical sector, potential investors should consider:
The company’s reliance on a single manufacturing facility
Mixed ratings from brokerages, indicating differing market opinions
Market volatility affecting listing gains
All information provided is for informational purposes only and should be independently verified with licensed financial advisors before making investment decisions.
Conclusion
The Anlon Healthcare IPO is one of the upcoming pharma sector offerings that investors are closely monitoring. With a fresh issue of 1.33 crore shares, a price band of Rs 86-91, and GMP of Rs 5, the IPO provides both opportunities and risks.
Retail and institutional investors can consider the company’s planned capacity expansion, industry growth prospects, and expert recommendations when deciding whether to subscribe. Proper research and cautious investment planning are advised to navigate IPO participation effectively.